Epstein Shochet Gali, Israeli-Shani Lilach, Koslow Matthew, Shitrit David
Pulmonary Department, Meir Medical Center, Kfar Saba, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pulmonary Department, Meir Medical Center, Kfar Saba, Israel.
Lung Cancer. 2016 Jun;96:7-14. doi: 10.1016/j.lungcan.2016.03.013. Epub 2016 Mar 26.
Nintedanib is a potent, triple angiokinase inhibitor of vascular endothelial growth factor, fibroblast growth factor, and platelet-derived growth factor, and has been recently approved for the treatment of non-small cell lung cancer (NSCLC), following first-line chemotherapy. It is well established that microenvironment plays an important role in tumor progression. Therefore, targeting tumor microenvironment-cancer cell interaction may provide a significant therapeutic target. In this study we tested the effect of Nintedanib on NSCLC cells directly and in the presence of normal and tumor soluble microenvironment.
Primary fibroblast cultures derived from NSCLC tumors and normal lung tissues were established and their supernatants were collected. These supernatants were added to NSCLC cell lines (H1299, H460 and A549) cultured with/without Nintedanib (0.1-10μM) for 24 and 48h. Cell death (AnnexinV-PI, flow-cytometry), cell number, proliferation (PCNA), protein expression (immunoblotting) and cell migration (scratch test), were tested. Expression of 10 pro-angiogenic cytokines was measured by ELISA-based quantitative array.
Tumor and normal supernatants demonstrated similar pro-metastatic effects on the NSCLC phenotype: both elevated cancer cell number, PCNA levels, reduced total and apoptotic cell death and facilitated cell migration. Nintedanib had limited but significant effects on the NSCLC cell number, cell death and migration, but required high doses. However, at lower doses Nintedanib caused cell detachment and elevated integrin-alpha 5 and EGFR levels, both markers of anoikis resistance. This suggests them as possible targets in combination with Nintedanib. Moreover, Nintedanib completely blocked the supernatants ability to facilitate the aggressive cancer cell characteristics. While cytokine array analysis showed no significant changes in FGF, PDGF or VEGF, we found that both supernatants contained high HGF levels, suggesting it as the facilitator of cell migration and proliferation.
Our results demonstrate that tumor microenvironment-cancer cell interaction is a therapeutic target and should be considered when new drugs are tested.
尼达尼布是一种强效的三重血管激酶抑制剂,可抑制血管内皮生长因子、成纤维细胞生长因子和血小板衍生生长因子,最近已被批准用于一线化疗后的非小细胞肺癌(NSCLC)治疗。众所周知,微环境在肿瘤进展中起重要作用。因此,靶向肿瘤微环境与癌细胞的相互作用可能提供一个重要的治疗靶点。在本研究中,我们直接以及在存在正常和肿瘤可溶性微环境的情况下测试了尼达尼布对NSCLC细胞的影响。
建立源自NSCLC肿瘤和正常肺组织的原代成纤维细胞培养物,并收集其上清液。将这些上清液添加到用/不用尼达尼布(0.1 - 10μM)培养24小时和48小时的NSCLC细胞系(H1299、H460和A549)中。检测细胞死亡(AnnexinV - PI,流式细胞术)、细胞数量、增殖(PCNA)、蛋白质表达(免疫印迹)和细胞迁移(划痕试验)。通过基于ELISA的定量阵列测量10种促血管生成细胞因子的表达。
肿瘤和正常上清液对NSCLC表型表现出相似的促转移作用:两者均增加癌细胞数量、PCNA水平,减少总细胞死亡和凋亡细胞死亡,并促进细胞迁移。尼达尼布对NSCLC细胞数量、细胞死亡和迁移有有限但显著的影响,但需要高剂量。然而,在较低剂量下,尼达尼布导致细胞脱离,并提高整合素α5和EGFR水平,这两者都是失巢凋亡抗性的标志物。这表明它们可能是与尼达尼布联合使用的潜在靶点。此外,尼达尼布完全阻断了上清液促进侵袭性癌细胞特征的能力。虽然细胞因子阵列分析显示FGF、PDGF或VEGF没有显著变化,但我们发现两种上清液中HGF水平都很高,表明它是细胞迁移和增殖的促进因子。
我们的结果表明,肿瘤微环境与癌细胞的相互作用是一个治疗靶点,在测试新药时应予以考虑。